NovMetaPharma Co., Ltd. (XKON:229500)

South Korea flag South Korea · Delayed Price · Currency is KRW
15,300
-100 (-0.65%)
Last updated: Oct 2, 2025, 9:00 AM KST
-0.65%
Market Cap185.52B
Revenue (ttm)1.30B
Net Income (ttm)408.03M
Shares Out12.13M
EPS (ttm)120.00
PE Ratio127.50
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,108
Average Volume5,065
Open15,690
Previous Close15,400
Day's Range14,550 - 15,690
52-Week Range4,600 - 17,890
Beta0.34
RSI49.29
Earnings Daten/a

About NovMetaPharma

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic diseases in South Korea. The company is developing NovDB2, a type 2 diabetes medication; NovOB, an anti-obesity medication; NovRD, a chronic kidney disease medication; NovFS, a fibrosis medication; and NovRF, a retroperitoneal fibrosis medication. It also develops drugs for inflammatory bowel; viral; vascular; bone loss; bone loss; cognitive impairment; Alzheimer’s; acute pancreatitis; degenerative brain; and liver cancer diseases, as well as cytokine inhibi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 229500
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.